Methylenetetrahydrofolate reductase 677 C→T polymorphism and plasma folate in relation to pre-eclampsia risk among Peruvian women

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 15, Issue 5, 2004, Pages 337-344

  Williams, M A ^a   Sanchez, S E ^b   Zhang, C ^a   Bazul, V ^c  

^a SWEDISH MEDICAL CENTER   (United States)

^b HOSPITAL NACIONAL DOS DE MAYO   (Peru)

^c Materno Perinatal Institute   (Peru)

Author keywords

FOLATE; METHYLENETETRAHYDROFOLATE REDUCTASE (MTHFR); PRE ECLAMPSIA

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); FOLIC ACID; VITAMIN;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FOLIC ACID BLOOD LEVEL; FOLIC ACID DEFICIENCY; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MATERNAL AGE; MOTHER FETUS RELATIONSHIP; NULLIPARA; PERU; PREECLAMPSIA; PREGNANCY; PREGNANT WOMAN; PRENATAL PERIOD; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; WILD TYPE;

ADULT; CASE-CONTROL STUDIES; FEMALE; FOLIC ACID; GENETIC PREDISPOSITION TO DISEASE; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); PERU; POINT MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PRE-ECLAMPSIA; PREGNANCY; QUESTIONNAIRES; RISK FACTORS;

EID: 3142694934     PISSN: 14767058     EISSN: None     Source Type: Journal    
DOI: 10.1080/14767050410001680037     Document Type: Article

References (45)

1. Rajkovic A, Catalano PM, Malinow MR. Elevated homocyst(e)ine levels with preeclampsia. Obstet Gynecol 1997;90:168-71
2. Rajkovic A, Mahomed K, Malinow MR, et al. Plasma homocyst(e)ine concentrations in eclamptic and preeclamptic African women postpartum. Obstet Gynecol 1999;94: 355-60
3. Sorensen TK, Malinow MR, Williams MA, et al. Elevated second-trimester serum homocyst(e)ine levels and subsequent risk of preeclampsia. Gynecol Obstet Invest 1999;48: 98-103
4. Powers RW, Evans RW, Majors AK, et al. Plasma homocysteine concentration is increased in preeclampsia and is associated with evidence of endothelial activation. Am J Obstet Gynecol 1998;179:1605-11
5. Dekker GA, de Vries JIP, Doelitzsch PM, et al. Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol 1995;173:1042-8
6. Malinow MR. Hyperhomocyst(e)inemia. A common and easily reversible risk factor for occlusive atherosclerosis. Circulation 1990;81:2004-6
7. Den Heijer M, Koster T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep vein thrombosis. New Engl J Med 1996;334:759-62
8. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. J Am Med Assoc 1997;277:1775-81
9. Moghadasian MH, McManus BM, Frohlich JJ. Homocysteine and coronary artery disease. Arch Intern Med 1997;157:2299-308
10. Heinecke JW, Rosen H, Suzuki LA, Chait A. The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J Biol Chem 1987;262:10098-103
11. Welch GN, Upchurch GR Jr, Farivar RS, et al Homocysteine-induced nitric oxide production in vascular smooth muscle cells by NF-κβ dependent transcriptional activation of Nos2. Proc Assoc Am Physicians 1998;110:22-31
12. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-13
13. Jacques PF, Bostom AG, Williams RR, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase and plasma homocysteine concentrations. Circulation 1996;93:1-9
14. Kluijtmans LA, van den Heuvel LP, Boers GH, et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996;58:35-41
15. Gallagher PM, Meleady R, Shields DC, et al. Homocysteine and risk of premature coronary heart disease. Evidence for a common gene mutation. Circulation 1996;94:2154-8
16. Sohda S, Arinami T, Hamada H, et al. Methylenetetrahydrofolate reductase polymorphism and pre-eclampsia. J Med Genet 1997;34:525-6
17. Grandone E, Margaglione M, Colaizzo D, et al. Factor V Leiden, C→T MTHFR polymorphism and genetic susceptibility to preeclampsia. Thromb Haemost 1997;77:1052-4
18. Powers RW, Minich LA, Lykins DL, et al. Methylenetetrahydrofolate reductase polymorphism, folate, and susceptibility to preeclampsia. J Soc Gynecol Investig 1999;6:74-9
19. 12 concentrations, and risk of preeclampsia among Black African women from Zimbabwe. Mol Genet Metab 2000;69:33-9
20. Chikosi AB, Moodley J, Pegoraro RJ, et al. 5,10 Methylenetetrahydrofolate reductase polymorphism in black South African women with pre-eclampsia. Br J Obstet Gynaecol 1999;106:1219-20
21. Kaiser T, Brennecke SP, Moses EK. C677T methylenetetrahydrofolate reductase polymorphism is not a risk factor for pre-eclampsia/eclampsia among Australian women. Hum Hered 2001;51:20-2
22. Kaiser T, Brennecke SP, Moses EK. Methylenetetrahydrofolate reductase polymorphisms are not a risk factor for preeclampsia/eclampsia in Australian women. Gynecol Obstet Invest 2000;50:100-2
23. Kim YJ, Williamson RA, Murray JC, et al. Genetic susceptibility to preeclampsia: roles of cytosineto-thymine substitution at nucleotide 677 of the gene for methylenetetrahydrofolate reductase, 68-base pair insertion at nucleotide 844 of the gene for cystathionine beta-synthase, and factor V Leiden mutation. Am J Obstet Gynecol 2001;184:1211-17
24. Kobashi G, Yamada H, Asano T, et al. Absence of association between a common mutation in the methylenetetrahydrofolate reductase gene and preeclampsia in Japanese women. Am J Med Genet 2000;93:122-5
25. Murakami S, Matsubara N, Saitoh M, et al. The relation between plasma homocysteine concentration and methylenetetrahydrofolate reductase gene polymorphism in pregnant women. J Obstet Gynaecol Res 2001;27:349-52
26. Murphy RP, Donoghue C, Nallen RJ, et al. Prospective evaluation of the risk conferred by factor V Leiden and thermolabile methylenetetrahydrofolate reductase polymorphisms in pregnancy. Arterioscler Thromb Vasc Biol 2000;20:266-70
27. O'Shaughnessy KM, Fu B, Ferraro F, et al. Factor V Leiden and thermolabile methylenetetrahydrofolate reductase gene variants in an East Anglian preeclampsia cohort. Hypertension 1999;33:1338-41
28. Prasmusinto D, Skrablin S, Hofstaetter C, et al. The methylenetetrahydrofolate reductase 677 C→T polymorphism and preeclampsia in two populations. Obstet Gynecol 2002;99:1085-92
29. Raijmakers MT, Zusterzeel PL, Steegers EA, Peters WH. Hyperhomocysteinaemia: a risk factor for preeclampsia? Eur J Obstet Gynecol Reprod Biol 2001;95:226-8
30. Rigo J Jr, Nagy B, Fintor L, et al. Maternal and neonatal outcome of preeclamptic pregnancies: the potential roles of factor V Leiden mutation and 5,10 methylenetetrahydrofolate reductase. Hypertens Pregnancy 2000;19:163-72
31. Zusterzeel PL, Visser W, Blom HJ, et al. Methylenetetrahydrofolate reductase polymorphisms in preeclampsia and the HELLP syndrome. Hypertens Pregnancy 2000;19: 299-307
32. Ware-Jauregui S, Sanchez SE, Zhang C, et al. Plasma lipid concentrations in preeclamptic and normotensive Peruvian women. Int J Gynecol Obstet 1999;67:147-55
33. Sanchez SE, Zhang C, Malinow MR, et al. Plasma folate, vitamin B12 and homocyst(e)ine concentrations in preeclamptic and normotensive Peruvian women. Am J Epidemiol 2001;153:474-80
34. Zhang C, Williams MA, Sanchez SE, et al. Plasma concentrations of carotenoids, retinol, and tocopherols in preeclamptic and normotensive pregnant women. Am J Epidemiol 2001;153:572-80.
35. American College of Obstetricians and Gynecologists. Hypertension in pregnancy. ACOG Tech Bull 1996;219:1-8
36. Rothman KJ, Greenland S. Modern Epidemiology, 2nd edn. Philadelphia, PA: Lippincott-Raven, 1998
37. Tiret L, Cambien F. Departure from Hardy-Weinberg equilibrium should be systematically tested in studies of association between genetic markers and disease. Circulation 1995;92:3364-5
38. Speer MC. Basics concepts in genetic. In Haines JL, Pericak MA, eds. Approaches to Gene Mapping in Complex Human Diseases. New York, NY: John Wiley & Sons, Inc., 1998:17-52
39. Schaid DJ, Jacobsen SJ. Biased tests of association: comparison of allele frequencies when departing from Hardy-Weinberg proportions. Am J Epidemiol 1999;149:706-11
40. Pepe G, Camacho Vanegas O, et al. Heterogeneity in world distribution of the thermolabile C677T mutation in 5,10-methylenetetrahydrofolate reductase. Am J Hum Genet 1998;63:917-20
41. Schneider JA, Rees DC, Liu YT, Clegg JB. Worldwide distribution of a common methylenetetrahydrofolate reductase mutation. Am J Hum Genet 1998;62:1258-60
42. Stevenson RE, Schwartz CE, Du YZ, Adams MJ Jr. Differences in methylenetetrahydrofolate reductase genotype frequencies, between Whites and Blacks. Am J Hum Genet 1997;60:229-30
43. Chesley LC, Annitto JE, Cosgrove RA. The remote prognosis of eclamptic women. Am J Obstet Gynecol 1976;124:446-59
44. Fisher K, Luger K, Spargo BH, Lindheimer MD. Hypertension in pregnancy: clinical-pathological correlations and late prognosis. Medicine (Baltimore) 1981;60:267-76
45. Jonsdottir LS, Arngrimsson R, Geirsson RT, et al. Death rates from ischemic heart disease in women with a history of hypertension in pregnancy. Acta Obstet Gynecol Scand 1995;74:772-6